To observe the efficacy and safety of Esculin and Digitalisglycosides eye drops on children′s abnormal blinking caused by visual display terminal.

A total of 96 children (192 eyes) with abnormal blinking caused by visual display terminal were randomly divided into two groups 48 cases (96 eyes) each in department of ophthalmology of Liaocheng Brain Hospital from January 2015 to December 2016. Of these, 61 were male (122 eyes) and 35 were female (70 eyes). Age ranged from 3 to 12 years, with an average age of (5.79±1.82) years. The course of disease ranged from 3 to 45 days, and the mean course of disease was (9.80±5.09) days. All newly diagnosed patients underwent routine examination of visual acuity, slit lamp, fundus and mydriasis optometry computer. The observation group was treated with Esculin and Digitalisglycosides eye drops, and the control group was treated with sodium hyaluronate eye drops, 1 drop into each eye 3 times daily for 20 days. The average number of blink, symptom score and drug safety evaluation were compared between the two groups before and at the end of treatment and analyzed statistically. Symptoms described by the mean and standard deviation (±s), and independent samples t-test was used to compare between groups using paired t-test to compare the group; treatment effect into four levels according to the cure, effective, effective and ineffective, the case number and percentage is described, comparison between groups by Kruskal-Wallis H test. Two groups of drug safety evaluation using χ² test.

Before treatment, the observation group with the symptom score was (4.02±2.18) points, the control group was (4.10±2.04) points, the two groups of children with symptoms were compared, the difference was not statistically significant (t₁=0.186, P₁>0.05). After treatment, the observation group with the symptom score was (0.38±0.64) points, the control group was (1.73±1.09) points, the two groups of children with symptoms were compared, the difference was statistically significant (t₁=7.400, P₁<0.05). After treatment, the symptom scores in the observation group were significantly better than those before treatment, the difference was statistically significant (t₂=10.048, P₂<0.05). After treatment, the symptom scores of the control group were significantly better than those before treatment, the difference was statistically significant (t₂=6.821, P₂<0.05). After treatment, the observation group was cured in 35 cases (70 eyes), markedly effective in 7 cases (14 eyes), effective in 2 cases (4 eyes), and ineffective in 4 cases (8 eyes). The total effective rate was about 87.50%. In the control group was cured in 17 cases (34 eyes), markedly effective in 12 cases (24 eyes), effective 6 cases (12 eyes) and invalid in 13 cases (26 eyes), the total effective rate was 60.42%. The clinical efficacy of the two groups of children before and after treatment were compared, the observation group was better than the control group, the difference was statistically significant (Hc=-2.30, P<0.05). In the observation group in 1 cases (2 eyes) of children with mild eye drops after tingling in the control group in 2 cases (4 eyes) of children with mild tingling or burning sensation, safety comparison by χ² test, the difference was not statistically significant (χ²=0.00, P>0.05). There were no serious complications and adverse reactions during the treatment of the two groups.

Esculin and digitalisglycosides eye drops can effectively relieve symptom of children′s abnormal blinking caused by visual display terminal, which is safe and convenient, thus it can be used in the clinical future. Yet it is necessary to carry out more large sample studys to observe its long-term efficacy and safety.